Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

/p>

On August 28, 2013, Alnylam Pharmaceuticals Inc. (Alnylam) announced the publication of complete study results from Phase I trials with ALN-TTR0a and ALN-TTR02 in a article titled "Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis" in the New England Journal of Medicine. Alnylam informed that the article shows that RNAi therapeutics targeting transthyretin (TTR) achieved rapid, dose-dependent, durable, and specific knockdown of the TTR, the disease causing protein in the TTR mediated amyloidosis (ATTR). Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam, said, "The Phase I studies of ALN-TTR01 and ALN-TTR02 demonstrate key human proof of concept for RNAi therapeutics targeting TTR but also for liver-expressed target genes in general, and we are thrilled to be publishing these landmark data in the New England Journal of Medicine. Notably, this is the first time that clinical results with an RNAi therapeutic have been published in the Journal, and we are proud to be associated with this milestone as we lead the clinical translation of RNAi therapeutics as a whole new class of innovative medicines." The Full Research Report on Alnylam Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for
    '/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... A. Martell , to the position of Executive Chairman. ... KaloBios Board of Directors. In this new role, he ... to refine and execute on the strategic plan to ... therapeutics for orphan oncology indications with high unmet medical ...
(Date:5/28/2015)... THE WOODLANDS, Texas , May 28, 2015 /PRNewswire/ ... announced today that Lexicon management will present at the ... at 8:00 a.m. Eastern Time in New ... of Lexicon,s clinical development programs and milestones. ... Lexicon,s website at www.lexpharma.com . An archived version ...
(Date:5/28/2015)... SOUTH SAN FRANCISCO, Calif. , May 28, 2015 ... the treatment of cancer, today announced that Sean ... at the upcoming Jefferies 2015 Global Healthcare Conference ... 2:30 p.m. EDT on Tuesday, June 2, 2015. Dr. ... including the company,s Precision cancer immunotherapy and Probody drug ...
Breaking Medicine Technology:KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5Lexicon To Present At The Jefferies 2015 Healthcare Conference 2
... FRANCISCO, July 21, 2011 ClinStar, LLC , ... and Eastern Europe to the pharmaceutical and biotechnology industry, ... speak at Marcus Evans 6th Annual Clinical Research ... FL.    (Logo: http://photos.prnewswire.com/prnh/20110719/SF36975LOGO ) ...
... July 21, 2011 Endologix, Inc. (NASDAQ: ELGX ... today announced financial results for the three and six months ... and Chief Executive Officer, said, "We are pleased with our ... our growth and new product development goals for 2011.  In ...
Cached Medicine Technology:ClinStar to Present on Conducting Clinical Trials in Russia 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 2Endologix Reports 22% Second Quarter 2011 Revenue Growth 3Endologix Reports 22% Second Quarter 2011 Revenue Growth 4Endologix Reports 22% Second Quarter 2011 Revenue Growth 5Endologix Reports 22% Second Quarter 2011 Revenue Growth 6Endologix Reports 22% Second Quarter 2011 Revenue Growth 7Endologix Reports 22% Second Quarter 2011 Revenue Growth 8Endologix Reports 22% Second Quarter 2011 Revenue Growth 9
(Date:5/28/2015)... Bronx, NY (PRWEB) May 28, 2015 ... Urgent Care are proud to present Dr. Alicia Almendral ... will be a big part of the newly opened ... very finest in modern cosmetic treatments. , Dr. Almendral ... experienced in the latest anti-aging and cosmetic enhancement techniques. ...
(Date:5/28/2015)... 28, 2015 Success Strategies for ... Process, **FDAnews Webinar**, June 23, 2015 — 11:00 ... , On June 23, 2015, FDAnews is offering ... intellectual property attorneys from the international law firm ... Biosimilars Approval: A Roadmap to the 351(k) Application ...
(Date:5/28/2015)... May 28, 2015 The Boys & Girls ... from Horizon Blue Cross Blue Shield of New Jersey (Horizon ... Gulbis, the club can receive much more support as play ... , A former Boys & Girls Club member and volunteer ... California, Ms. Gulbis has accepted the Horizon Blue Cross Blue ...
(Date:5/28/2015)... AMVETS leaders this week congratulated AMVETS 2015 Memorial ... Newark, Del. AMVETS National Commander Larry Via personally called ... sweepstakes grand prize. , AMVETS selected the 10 lucky ... country for prizes ranging from $500 to the $10,000 ... at the AMVETS National Headquarters in Lanham, MD. , ...
(Date:5/28/2015)... 2015 As the summer approaches, many people ... It’s important to make safety a top priority, however, and ... tips. , According to the Centers for Disease Control, 10 ... not including boating incidents. Additionally, the National Safety Council says ... 1 to 4. , Amica is sharing the following ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 3Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 2Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Splash! Amica Shares 6 Swimming Safety Tips 2
... when kidneys are damaged, study finds, , , WEDNESDAY, Jan. ... at a greater risk of heart failure, stroke and other ... University of Glasgow study of adults ages 70 to 82 ... a three times greater risk of having non-fatal heart failure ...
... synthetic chemical version of what male sea lampreys use ... and foil the mating process of the destructive invasive ... chemical scents used to attract a mate, are well-documented ... fisheries and wildlife, has focused much of his career ...
... 21 Erdman, A Cogdell,Spencer Company, a subsidiary of ... it broke ground earlier this week on two new ... feet. , The two projects, ... in Jackson, Tennessee and a $1.75 million cancer center ...
... Market Intelligence and Competitive Analysis from Thomson Reuters to ... and LONDON, Jan. 21 /PRNewswire/ -- Thomson ... businesses and professionals, has announced the availability of three ... July - September 2008. The quarterly Pharma Matters ...
... Calif., Jan. 21 Human Pheromone,Sciences, Inc. (OTC ... it has established a website devoted to its ... Company filed Comprehensive Patent,Applications with both the U.S. ... the World Patent Office. On the site, the ...
... the "hands down winner"SANTA FE, N.M., Jan. 21 ... best health information search engine by AltSearchEngines.com , ... Mednar (still in beta) debuted in November ... professional medical researchers. It enables users to quickly access ...
Cached Medicine News:Health News:Chemical come-on successfully lures lovesick lampreys to traps 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 3Health News:Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008 2Health News:Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008 3Health News:HPS Establishes Independent Website for its Patent-Pending Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:Deep Web Technologies' Mednar Is Rated the #1 Alternative Health Search Engine 2Health News:Deep Web Technologies' Mednar Is Rated the #1 Alternative Health Search Engine 3
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
SHERIDAN PREFORMED™ Endotracheal Tubes are designed to conveniently position the anesthesia circuit out of the surgical field for oral and maxillofacial procedures....
Nasal soft cuffed endotracheal tubes designed and constructed especially for long-term nasal intubations....
... is the next step in the ... is an easy to use, easy ... used as a standard tube, as ... quickly and safely handle intubations of ...
Medicine Products: